The FDA has accepted for filing and granted standard review status to its supplemental Biologics License Application (sBLA) for Xiaflex...
Actelion will acquire from Auxilium Pharma exclusive rights to commercialise Xiaflex (collagenase Clostridium histolyticum) as a treatment for two rare...
New data from the IMPRESS Phase III studies that assessed Xiaflex (collagenase clostridium histolyticum or CCH), from Auxilium Pharmaceuticals, for...
The FDA has approved the supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner, Auxilium Pharmaceuticals for Xiaflex (collagenase clostridium...
Auxilium Pharmaceuticals has submitted a supplemental Biologics License Application (sBLA) to the FDA requesting approval of Xiaflex (collagenase clostridium histolyticum),...
Data from multiple trials evaluating the use of Xiaflex/Xiapex (collagenase clostridium histolyticum), from Auxilium Pharma and SOBI, in adult patients...
Results of the MULTICORD open-label Phase IIIb study (AUX-CC-867) demonstrated that two concurrent injections of Xiaflex (collagenase clostridium histolyticum or...
Auxilium Pharmaceuticals has announced positive data for Xiaflex (clostridial collagenase injection), from Auxilium Pharma, for the treatment of adults with...
The phase III IMPRESS studies of Xiaflex (clostridial collangase for injection), from Auxilium Pharma, for treatment of Peyronie's Disease (PD)...
Auxilium Pharmaceuticals has announced data from new studies, as well as new analyses of data from the Phase II and...